SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Izzy who wrote (2686)11/7/1997 9:15:00 PM
From: Oliver & Co  Read Replies (1) of 6136
 
Hi Izzi, just back from the conference. Much new information. Good news and bad news.
Unfortunately, no cure in sight. Vaccines 10 to 20 years away. New SHIV(Simian-Human Immunodeficiency Virus) made to do vaccine testing, pathogenic.
Much failure seen with all types of therapy. Three important factors, CD45RO(memory)CD4 lymphocytes, "Beware the Sins of the Past," and adherence.
From what I see, HIV/AIDS will be around for a long, long time. All the new coming drugs are more of the same,albeit improved.
New viral load threshold @less than 20 copies.
Patients who will do better will be those started on multi-drug cocktails, with perfect adherence. Treatment indefinetly.
Proof of no resistance 2 years into treatment.
No new drugs until mid-late 1998.
DMP 266, Amprenavir, or 141 in phase III& 1592(Abacavir).

JLL
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News